AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
A phase 1 study of OKI-219 reads out imminently.
Bristol will test the bispecific in two new lung indications.
New pivotal trials of HRS-8080 are planned in first-line and adjuvant breast cancer.
After Genmab’s exit two more ADCs enter human trials.
A new phase 3, Manifest-3, will start in April to support US filing.
The company takes a PD-L1 x VEGF asset into phase 3.
